FKBPL and its peptide derivative, ALM201, are shown to decrease the migration and invasion of breast cancer stem cells (CSC) and inhibit the growth of mammospheres of endocrine therapy-resistant breast CSC [12,13]. This evidence concerns the gene FKBPL and breast carcinoma.